BioCryst Pharmaceuticals, Inc. (BCRX)Healthcare | Drug Manufacturers - Specialty & Generic | Durham, United States | NasdaqGS
8.02 USD
-0.03
(-0.373%) ⇩
(Oct. 15, 2026, 4 p.m.
EDT)
After hours: 8.02 |
Hot Take ↕ | Oct. 10, 2026, 7:37 a.m. EDT
BioCryst presents a compelling turnaround story driven by operational execution rather than speculative hype. The company has successfully navigated a severe multi-year price correction, with the stock trading significantly above its 200-day moving average and showing positive year-over-year momentum. Fundamentally, the business is robust: revenue is growing at a healthy 33.6%, operating margins are expanding to 45%, and free cash flow is strong enough to support operations without dilution. The balance sheet is healthy with a current ratio above 2.0, and the forward P/E of roughly 9x suggests the market is pricing in a cautious path to profitability rather than demanding a premium for growth. However, the short-term outlook remains neutral due to the lack of a clear catalyst beyond the upcoming earnings report and the hiring of a Chief Scientific Officer to bolster the pipeline. While analysts see significant upside potential, the stock has not yet demonstrated the explosive momentum required to justify a bullish entry. The absence of a dividend yield further limits its appeal as a defensive hold. Investors should view this as a solid mid-cap biotech play waiting for the next clinical milestone to unlock the full value of its pipeline, but it lacks the immediate urgency for a high-conviction trade. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.061306 |
| AutoETS | 0.061783 |
| AutoARIMA | 0.061812 |
| AutoTheta | 0.062220 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 41% |
| H-stat | 3.92 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.185 |
| Excess Kurtosis | -1.16 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Revenue per Share | 4.099 |
| Market Cap | 2,049,391,616 |
| Forward P/E | 8.53 |
| Beta | 0.55 |
| Profit Margins | -40.90% |
| Website | https://www.biocryst.com |
As of Oct. 10, 2026, 7:37 a.m. EDT: Speculators are positioning for a range-bound recovery rather than a breakout. Call volume is heavily skewed toward out-of-the-money strikes (over 90% of open interest), indicating bets on a move higher, yet put open interest remains substantial at lower strikes, creating a 'straddle' bias. The heavy concentration of call open interest at $10 and $13 suggests a ceiling expectation, while the lack of deep in-the-money call volume implies skepticism about an immediate surge above current levels.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.19791663 |
| Address1 | 4,505 Emperor Boulevard |
| Address2 | Suite 200 |
| All Time High | 37.25 |
| All Time Low | 0.6 |
| Ask | 9.22 |
| Ask Size | 1 |
| Audit Risk | 8 |
| Average Analyst Rating | 1.5 - Buy |
| Average Daily Volume10 Day | 4,637,510 |
| Average Daily Volume3 Month | 4,083,987 |
| Average Volume | 4,083,987 |
| Average Volume10Days | 4,637,510 |
| Beta | 0.548 |
| Bid | 6.88 |
| Bid Size | 1 |
| Board Risk | 3 |
| Book Value | -1.78 |
| City | Durham |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 10 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 8.02 |
| Current Ratio | 2.321 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 8.23 |
| Day Low | 7.945 |
| Display Name | BioCryst Pharmaceuticals |
| Dividend Yield | 0.0 |
| Earnings Call Timestamp End | 1,785,933,000 |
| Earnings Call Timestamp Start | 1,785,933,000 |
| Earnings Growth | 14.0 |
| Earnings Quarterly Growth | 14.417 |
| Earnings Timestamp | 1,785,933,000 |
| Earnings Timestamp End | 1,793,622,600 |
| Earnings Timestamp Start | 1,793,622,600 |
| Ebitda | 433,047,008 |
| Ebitda Margins | 0.46039 |
| Enterprise To Ebitda | 5.868 |
| Enterprise To Revenue | 2.702 |
| Enterprise Value | 2,541,129,472 |
| Eps Current Year | 0.745 |
| Eps Forward | 0.94 |
| Eps Trailing Twelve Months | -1.4 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fax | 919 859 1314 |
| Fifty Day Average | 9.054 |
| Fifty Day Average Change | -1.0339994 |
| Fifty Day Average Change Percent | -0.11420361 |
| Fifty Two Week Change Percent | 19.791662 |
| Fifty Two Week High | 11.22 |
| Fifty Two Week High Change | -3.1999998 |
| Fifty Two Week High Change Percent | -0.28520498 |
| Fifty Two Week Low | 6.23 |
| Fifty Two Week Low Change | 1.7900004 |
| Fifty Two Week Low Change Percent | 0.28731948 |
| Fifty Two Week Range | 6.23 - 11.22 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 762,791,400,000 |
| Float Shares | 222,315,541 |
| Forward Eps | 0.94 |
| Forward P E | 8.531916 |
| Free Cashflow | 323,666,752 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 435 |
| Fullday Change | -0.029999733 |
| Fullday Change Percent | -0.3726675 |
| Fullday Price | 8.02 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,790,812,800 |
| Gross Margins | 0.77388 |
| Gross Profits | 727,923,008 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.01277 |
| Held Percent Institutions | 1.0534301 |
| Implied Shares Outstanding | 255,535,105 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Industry Disp | Drug Manufacturers - Specialty & Generic |
| Industry Key | drug-manufacturers-specialty-generic |
| Ir Website | http://investor.shareholder.com/biocryst/index.cfm |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | BioCryst Pharmaceuticals, Inc., a biotechnology company, developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated and seasonal influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat HAE. It is also developing BCX17725, a protein therapeutic for netherton syndrome which is in phase 1; Avoralstat, an ocular plasma kallikrein inhibitor for diabetic macular edema that is in Phase 1; Navenibart, a monoclonal antibody plasma kallikrein inhibitor for HAE which is in Phase 3; BCX17725, an investigational protein therapeutic KLK5 inhibitor for the treatment of netherton syndrome that is in phase 1 clinical trial; STAR-0310, a monoclonal antibody OX40 antagonist for the treatment of atopic dermatitis which is in Phase 1a trial. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd., Shionogi & Co., Ltd., and Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina. |
| Long Name | BioCryst Pharmaceuticals, Inc. |
| Market | us_market |
| Market Cap | 2,049,391,616 |
| Market State | POST |
| Max Age | 86,400 |
| Message Board Id | finmb_25594 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -384,672,992 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 2,186,102,823 |
| Number Of Analyst Opinions | 11 |
| Open | 8.105 |
| Operating Cashflow | 376,135,008 |
| Operating Margins | 0.45116 |
| Overall Risk | 8 |
| Payout Ratio | 0.0 |
| Peg Ratio | 9.39 |
| Phone | 919 859 1302 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 8.02 |
| Post Market Time | 1,792,099,986 |
| Previous Close | 8.05 |
| Price Eps Current Year | 10.765101 |
| Price Hint | 2 |
| Price To Book | -4.505618 |
| Price To Sales Trailing12 Months | 2.178783 |
| Profit Margins | -0.40895998 |
| Quick Ratio | 2.219 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | buy |
| Recommendation Mean | 1.54545 |
| Region | US |
| Regular Market Change | -0.029999733 |
| Regular Market Change Percent | -0.37266746 |
| Regular Market Day High | 8.23 |
| Regular Market Day Low | 7.945 |
| Regular Market Day Range | 7.945 - 8.23 |
| Regular Market Open | 8.105 |
| Regular Market Previous Close | 8.05 |
| Regular Market Price | 8.02 |
| Regular Market Time | 1,792,094,401 |
| Regular Market Volume | 4,501,008 |
| Return On Assets | 0.52861 |
| Revenue Growth | 0.336 |
| Revenue Per Share | 4.099 |
| Sand P52 Week Change | 0.16440773 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 255,535,105 |
| Shares Percent Shares Out | 0.1076 |
| Shares Short | 27,494,721 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 34,050,906 |
| Short Name | BioCryst Pharmaceuticals, Inc. |
| Short Percent Of Float | 0.1084 |
| Short Ratio | 5.15 |
| Source Interval | 15 |
| State | NC |
| Symbol | BCRX |
| Target High Price | 32.0 |
| Target Low Price | 11.0 |
| Target Mean Price | 20.72727 |
| Target Median Price | 17.0 |
| Total Cash | 352,572,992 |
| Total Cash Per Share | 1.38 |
| Total Debt | 836,644,992 |
| Total Revenue | 940,612,992 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.4 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 8.71145 |
| Two Hundred Day Average Change | -0.69144917 |
| Two Hundred Day Average Change Percent | -0.07937246 |
| Type Disp | Equity |
| Volume | 4,501,008 |
| Website | https://www.biocryst.com |
| Zip | 27,703 |